A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of...
Saved in:
Published in | Biomolecules (Basel, Switzerland) Vol. 11; no. 12; p. 1749 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
23.11.2021
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!